Collaborative Practice
| Collaborative Drug Therapy Management Policy 9903 11/01/1999 Introduced 03/01/2004 Reapproved 12/01/2008 Reapproved 06/01/2011 Revised 10/01/2012 Reapproved 10/18/2021 Revised | AMCP supports the concept of collaborative drug therapy management (CDTM) a formal partnership between a pharmacist and a prescriber that allows the pharmacist to manage a patient’s drug therapy. CDTM, also referred to as collaborative practice, allows pharmacists to use their unique skills and abilities to complement other types of care provided by collaborating professionals to optimize patient outcomes. When pharmacists practice under CDTM agreements, health care services and outcomes are optimized when compared with settings where pharmacists were not involved. (See AMCP Managed Care Pharmacy Practice Positions – Collaborative Drug Therapy Management)
|
| Disease Management Policy 9907 11/01/1999 Introduced 03/01/2004 Reapproved 12/01/2008 Revised 10/01/2012 Revised 02/21/2018 Revised | AMCP supports disease management as the concept of reducing health care costs, closing gaps in care, and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated medical and pharmacy management. Disease management programs are designed to improve health outcomes and reduce associated costs from avoidable complications and medication adverse events by identifying and treating chronic conditions more quickly and effectively, and improving appropriate medication use and adherence, thus slowing the progression of those diseases. AMCP recognizes that, as a trained medication management specialist, the pharmacist has clinical expertise and a leadership role to play in the collaborative development, implementation and improvement of disease management programs.
(See AMCP Managed Care Pharmacy Practice Positions – Disease Management)
|
| Evidence-based Clinical Practice Guidelines Policy 0007 02/01/2000 Introduced 02/01/2005 Reapproved 11/01/2009 Reapproved 02/21/2018 Revised | AMCP advocates direct involvement of pharmacists in the development, evaluation, and implementation of evidence-based clinical practice guidelines that focus on an interdisciplinary team approach to patient care.
|
| Health Care Team Approach to Optimal Therapeutic Outcomes Policy 0014 02/01/2000 Introduced 02/01/2005 Reapproved 02/01/2010 Reapproved 04/07/2015 Revised | AMCP believes that achieving optimal therapeutic outcomes for each patient is a shared responsibility of the health care team. AMCP further supports the active role of the pharmacist in the development, implementation and monitoring of therapeutic plans, which include provider communication and assisting patients to become informed decision makers to improve adherence with their prescribed therapeutic plan.
|
Pharmacogenomics
| AMCP supports further research and assessment of the economic, clinical, and humanistic impact of pharmacogenomics on managed care pharmacy practice. AMCP supports the pharmacist's leadership role in the review and evaluation of scientific evidence and the subsequent development of pharmaceutical care processes involving these therapies through collaboration with other health care practitioners and consumer organizations. Pharmacy and Therapeutics Committees in collaboration with Health Technology Assessment committees should be involved in the decision-making process related to coverage of genetic tests and utilization management strategies. |
| Pharmacy Benefits for the Uninsured/Underinsured Policy 0118 11/01/2001 Introduced 02/01/2006 Revised 12/01/2010 Reapproved 03/25/2019 Revised 10/16/2023 Revised | AMCP supports the appropriate access to medications and the development of integrated systems to ensure access to enhanced pharmacy services and pharmaceutical products for all patients, regardless of insurance coverage or income.
|
| Therapeutic Interchange Policy 9928 11/01/1999 Introduced 03/01/2004 Reapproved 12/01/2008 Reapproved 10/01/2012 Revised 03/25/2019 Revised 02/08/2024 Revised | AMCP supports the use of evidence-based therapeutic interchange programs as a part of a comprehensive approach to quality, cost-effective patient care. AMCP believes that therapeutic interchange may improve the patient's access to more affordable health care and represents an efficient use of pharmaceutical resources that helps keep medical costs down. The therapeutic interchange programs are designed to work in conjunction with other tools that health care professionals use to promote quality medical outcomes and increase affordability to patients and payers. Therapeutic interchange is not always about simply lowering the medication costs; however, therapeutic interchange frequently occurs when overall health care savings can be achieved. There are instances where replacing one drug with a more costly drug may result in fewer treatment failures, better patient adherence to the treatment plan, fewer side effects, and improved clinical outcomes, which could result in lower overall health care spending. (See AMCP Managed Care Pharmacy Practice Positions – Therapeutic Interchange). |
| Emergency Response Policy 0303 11/01/2003 Introduced 02/01/2008 Revised 10/01/2012 Revised 10/28/2022 Revised | AMCP recognizes that pharmacists, as medication management experts, play a vital role in maintaining and promoting public health, especially during a public emergency. Therefore, AMCP supports pharmacists practicing at or above the full scope of their license during a national emergency through the continued efforts of the state boards of pharmacy, state and federal governments, and military agencies. AMCP also encourages pharmacists to participate in National Disaster Medical Assistance Teams and serve on local units of Medical Reserve Corp to respond to national and local emergencies. |
Transitions of Care
Policy 2002
11/17/2020 Introduced | Transition of care is the movement of patients from one health care practitioner or setting to another as their condition and care needs change. It occurs 1) within settings, such as primary care and specialty care in the context of care in the community, 2) between settings, such as someone who moves from the hospital to the rehabilitation facility, and it occurs 3) based on health status, such as moving from curative to palliative care. AMCP supports the role of pharmacists in ensuring the continuity of a patient’s medication therapy regimen when moving among these diverse health care settings. Pharmacists analyze and communicate information about the safety, effectiveness and outcomes of drug therapy to other health care providers to ensure appropriate continuity of drug therapy. Additionally, pharmacists serve the needs of patients and caregivers by providing consultation that helps them understand their medication, the dosing and possible side effects while encouraging adherence as the patient moves from one setting to another. |
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
